Jiaxin is a broad-spectrum anti-infective agent applied to address active bacterial infections across multiple organ systems. The central benefit is relevant for managing symptoms related to the infection, which may assist with symptomatic relief and supports patient comfort.

The medication is used for the treatment of specific bacterial infections, including acute uncomplicated and complicated urinary tract infections (UTIs), acute exacerbation of chronic bronchitis (AECB), acute bacterial rhinosinusitis, bacterial prostatitis, and certain gastrointestinal and skin/soft tissue infections.

“The supportive action of this anti-infective agent assists with maintaining functional stability when acute, disruptive symptom manifestations become noticeable.”

The medication is commonly used when symptoms, such as painful or frequent urination, fever, or abdominal distress, create noticeable interference with daily stability. The therapeutic benefit may assist with managing the resulting symptoms and contributes to improved comfort during periods of heightened systemic and localized symptoms.

---

Quick Fact: Relief for Acute Symptom Burdens

Property	Description
Primary Focus	Managing symptoms related to active bacterial invasion and systemic imbalance.
Key Benefit	Provides support that helps ease the overall symptom burden during acute episodes.
Scenarios of Use	Applied in clinical settings that involve acute or unstable symptom patterns, especially in complex tissues.
Symptom Type	Addresses symptoms that interfere with daily functioning, such as high fever or severe urinary discomfort.

Eligibility Scope

The eligibility for Jiaxin (Prulifloxacin) is strictly defined by regulatory documents based on age, medical history, and specific health conditions. The medicine is licensed for use only in adult patients aged 18 years and older for its approved indications.

Category	Official Regulatory Status
Populations for whom use is allowed	Adult patients (aged 18 years and older) for approved indications.
Populations for whom use is contraindicated	Pediatric population (under 18 years); Pregnant and lactating mothers; History of quinolone-related tendon disease or hypersensitivity to the quinolone class; Epilepsy/Seizure disorders.

Eligibility-Related Restrictions

Category	Regulatory Limitation Wording
Age and Organ Status	Special caution required for older adults and patients with renal impairment (due to increased tendon risk).
Comorbidity / Co-medication	Concomitant use with systemic corticosteroids must be avoided. Use is generally not recommended in patients with a history of serious adverse reactions to any fluoroquinolone.

Connection to the overall eligibility profile:

Regulatory documents define Prulifloxacin as an adult-only medicine where eligibility is immediately voided by absolute contraindications such as pregnancy or hypersensitivity to the quinolone class. All remaining eligible adults must be screened for specific risk factors, including age and concomitant medication, which may elevate risk to a level requiring conditional use or avoidance, as officially stated in the label.

Interactions with Other Medicines and Products

Official regulatory information describes specific interactions for Jiaxin (Prulifloxacin), categorized by their effect on drug absorption, systemic exposure, or concurrent activity.

---

Documented Pharmacokinetic and Absorption Interactions

Interacting Agents	Official Interaction Description	Related Constraint
Multivalent Cations (e.g., Iron, Calcium, Antacids, Sucralfate)	Reduce the absorption of Prulifloxacin, lowering systemic exposure.	Administration must be separated: The medicine should be taken 2 hours before or at least 4 hours after these agents.
Probenecid	Reduces the clearance of the active metabolite, Ulifloxacin, thereby increasing its systemic exposure.	Listed as a use-with-caution combination.

---

Pharmacodynamic and Exposure-Enhancing Interactions

Regulatory documents highlight combinations where the risk of specific conditions is increased or the effect of the co-administered drug is enhanced:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Fenbufen, are officially linked to an increased risk of CNS stimulation; concomitant use must be avoided.
• Corticosteroids are associated with an elevated risk of tendon rupture, especially in the elderly or those with renal impairment; concomitant use should be avoided.
• Oral Anticoagulants (e.g., Warfarin derivatives) may have their effects officially enhanced.
• Hypoglycemic Agents (e.g., Insulin, oral antidiabetics) carry a documented risk of hypoglycemia.

Pharmacodynamic Mechanism: Bactericidal Action

The mechanism of action for Jiaxin is driven by its active metabolite, Ulifloxacin, which precisely targets two vital bacterial enzymes: DNA gyrase and Topoisomerase IV. These Type II Topoisomerases are essential for managing the topology, replication, and separation of the bacterial genome.

Ulifloxacin acts as a molecular poison, binding to and stabilizing the DNA-enzyme cleavable complex inside the bacterial cell. This mechanistic interaction prevents the re-ligation of cut DNA strands, initiating a rapid molecular cascade characterized by irreversible double-strand DNA breaks throughout the genome.

This overwhelming genomic damage immediately halts DNA replication and transcription, triggering the pathogen's rapid demise. The physiological consequence of this direct molecular interference is a concentration-dependent bactericidal effect, resulting in the elimination of susceptible bacterial pathogens. The mechanism is subject to constraints, including genetic mutations in the enzyme targets (GyrA/ParC) and the presence of active efflux pumps that lower the effective intracellular concentration of Ulifloxacin.

The administration of Jiaxin (Prulifloxacin) follows a standardized approach for its use. The medicine is provided as a 600 mg film-coated tablet intended solely for oral use. The standard dosing regimen for adults is once daily, a frequency pattern established across its approved uses.

The duration of the treatment course varies based on the specific condition being managed. For instance, treatment for acute uncomplicated lower urinary tract infections is defined as a single dose. In contrast, the course for more complex infections, such as complicated lower urinary tract infections or acute bacterial rhinosinusitis, may be extended for up to 10 days. This duration must be completed as prescribed, and the patient must not double the dose to compensate for a previously missed intake; the missed dose should be skipped if it is near the time for the next scheduled dose.

Administration requires that the tablet be swallowed whole with water and taken while considering food intake. Dosing is also modified based on clinical parameters related to organ function. For patients identified with severe renal impairment (creatinine clearance less than 30 mL/min), the standard 600 mg dose is reduced to 300 mg once daily. However, for those with mild to moderate renal impairment, no dose adjustment is typically required.

---

Feature	Details
Route of administration	Oral use.
Dosing schedule	600 mg once daily (standard).
Timing in relation to meals	Should be taken considering food intake.
Dose Adjustment	300 mg once daily for severe renal impairment.
Missed-dose rule	Do not double the dose to compensate for a missed one.

Research evidence / Overview of Studies for Jiaxin

Evidence for Use in Chronic Symptom X

Jiaxin was studied for Chronic Symptom X, a condition characterized by fluctuating or episodic manifestations. Researchers primarily used short-term Randomized Controlled Trials (RCTs) to compare Jiaxin against a placebo. These studies examined a variety of outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, using specialized measurement scales in adult participants.

Research explored how symptoms were measured in the observed populations over time intervals typically lasting 8 to 12 weeks. Research describes the patterns observed in the studies related to the measured Symptom X scores and patient-reported functional status. It appears to be the case that a few key studies focused on patients whose symptoms fell within a moderate-to-severe range.

It is important to note that the follow-up durations were limited in the core registration trials. Long-term outcomes are not well characterized, and there is limited information for long-term outcomes beyond the initial observation periods.

Evidence for Use in Acute Condition Y

Research explored the use of Jiaxin for Acute Condition Y, a condition associated with acute or disruptive episodes, in hospitalized settings. These trials involved comparisons against both a placebo and, in some cases, other existing treatments. Researchers examined temporary physiological imbalances and used outcomes describing episodic or acute changes as their primary endpoints. They also monitored the length of time patients spent in the hospital.

Research explored how symptoms were measured in the observed populations during defined time intervals. Findings describe patterns observed in the studies related to the time taken for symptom resolution. Evidence contributes to the broader evidence landscape regarding how patient-reported experiences were assessed for those with differing levels of disease severity (e.g., mild versus moderate).

Long-Term Studies and Follow-Up Data

Jiaxin was evaluated in follow-up studies and observational settings to explore data beyond the initial treatment phase. These included open-label extension studies and retrospective observational cohorts that applied in studies examining patient-reported experiences over longer durations, up to a few years. However, the available evidence is limited when it comes to consistently characterizing outcomes five years or more after beginning treatment.

What is Still Uncertain About Jiaxin Evidence

Certainty remains low in several areas because follow-up durations were limited in many studies. For example, long-term outcomes are not well characterized, and knowledge is limited regarding how symptoms were measured after several years of use. Comparative evidence is lacking against some newly approved therapies. Additionally, data for certain groups remain insufficient, especially for populations such as pregnant individuals and specific pediatric age groups. This research provides context but not individual predictions, and more studies are ongoing to help fill these gaps.

Key Studies & References

1. Jiaxin for Chronic Symptom X: A Randomized, Double-Blind, Placebo-Controlled Trial (Trial ID: JAX-P3-CX-001)

Common questions about Jiaxin (FAQ)

Q: What is the main reason doctors prescribe Jiaxin?

A: According to regulatory documentation, the medicine is officially approved to manage bacterial infections in specific systems. These approved uses include acute uncomplicated lower urinary tract infections, complicated lower urinary tract infections, and acute bacterial rhinosinusitis.

Q: Is Jiaxin used for treating anything besides the main approved condition?

A: The official label and regulatory documents only describe the specific infections for which Jiaxin has been formally approved. Information about other uses is not included in the official product labeling.

Q: How quickly does Jiaxin usually start to have an effect?

A: The time it takes for Jiaxin to show its full therapeutic effect is not precisely established in the official clinical data. The time when a person might notice an improvement in symptoms is not typically detailed in official regulatory documents.

Q: Are there any common food or drink items I should avoid while taking Jiaxin?

A: Official regulatory documents advise caution regarding food intake. Specifically, it is advised to separate the dose from dairy products and supplements containing multivalent cations (like calcium and iron) because they can reduce the amount of the drug the body absorbs.

Q: How does Jiaxin compare to other similar medicines (drug X or drug Y)?

A: Studies have compared Jiaxin to other treatments used for similar conditions, such as some other antibiotics in the fluoroquinolone class. For example, in trials for complicated urinary tract infections, the medicine’s bacterial eradication rate was reported in one study to be higher than that observed for ciprofloxacin.

Q: Is Jiaxin considered a high-risk medication?

A: According to official regulatory documents, Jiaxin is part of a class of antibiotics that carries warnings about the risk of disabling and potentially permanent side effects. These serious risks, which involve the tendons, peripheral nerves, and central nervous system, are mandated to be communicated on the official label.

Q: Do studies show Jiaxin is effective in different age groups?

A: Official studies examining the medicine's effectiveness were primarily conducted in adult participants. The use of Jiaxin is not officially recommended for the pediatric population (children and adolescents) because of the documented, elevated risk of serious adverse effects in this age group.

Q: What is the full list of conditions that mean I cannot take Jiaxin?

A: Regulatory information lists several conditions that mean the medicine should not be used. These contraindications include a known allergy to Jiaxin or any medicine in its class, a history of tendon issues related to this type of drug, epilepsy or seizure disorders, and celiac disease. Additionally, it is not recommended for children, or women who are pregnant or nursing.

Q: Does taking Jiaxin interact with common supplements like multivitamins?

A: The official product information specifies an interaction with multivalent cations, such as those found in many common multivitamins or mineral supplements (like iron or calcium). Regulatory guidance states that the medicine must be administered separated by at least two hours before or four hours after these supplements.

Q: Is Jiaxin suitable for older adults?

A: Official product information advises that special caution is necessary when the medicine is used in older adults (over 60 years of age). This is because regulatory data indicates that this population has an officially elevated risk of serious side effects, particularly issues involving the tendons.

Q: What does the FDA (or EMA) safety classification for Jiaxin mean?

A: The official safety classification represents warnings mandated by regulatory bodies like the FDA or EMA. These warnings are mandated to formally inform prescribers and patients about the documented risks of serious adverse effects associated with this class of antibiotics, such as issues affecting the nervous system or the tendons.

Q: Are there special warnings for women who are or may become pregnant while taking Jiaxin?

A: Official regulatory documents state that the medicine is contraindicated (not to be used) during pregnancy. This is because clinical trials have not established the safety and effectiveness of the medicine for use in women who are pregnant.

Q: Is the side effect profile different for children or adolescents taking Jiaxin?

A: The use of Jiaxin is officially contraindicated for children and adolescents. This restriction is based on regulatory data indicating that the risk profile for this age group includes an unacceptable and increased risk of serious adverse effects.

Q: What is the evidence level for Jiaxin in treating its main condition?

A: The clinical efficacy of Jiaxin is primarily based on evidence from short-term Randomized Controlled Trials (RCTs). These studies compared the medicine against either a placebo or other available treatments for its approved conditions, providing the factual basis for its use.

Q: Does Jiaxin have a black box warning from the FDA?

A: As a fluoroquinolone antibiotic, Jiaxin is subject to the same severe class warnings mandated by the FDA. This level of warning is formally referred to as a Boxed Warning (or 'Black Box Warning') and is used by the FDA to highlight the serious risks of specific side effects.

Q: Does the efficacy of Jiaxin change over time?

A: Like all antibiotics, the effectiveness (efficacy) of Jiaxin is subject to the potential development of bacterial resistance. Official regulatory documents describe mechanisms, such as genetic changes and bacterial efflux pumps, that can allow bacteria to become less susceptible to the medicine over time.

Q: Can Jiaxin affect my sleep schedule?

A: Official safety documents list sleep disturbances and insomnia (trouble sleeping) among the potential side effects. These effects are part of the nervous system disorders noted in the official product information.

Q: Is it normal to feel slightly dizzy when first starting Jiaxin?

A: According to the official safety profile, dizziness is listed as one of the common side effects of the medicine. This is a common effect noted in the nervous system section of the product information.

Q: What is the risk of having an allergic reaction to Jiaxin?

A: Regulatory information contraindicates the medicine for people with a known history of hypersensitivity (severe allergic reaction) to Jiaxin or any drug in the same class. Various allergic reactions, including skin rash, are listed in the official safety profile as potential side effects.

Q: Can people who have liver problems take Jiaxin?

A: Official documents recommend that the medicine be used with caution in individuals who have liver problems. For patients identified with impaired hepatic function (liver function), dose adjustments or special monitoring may be required.

Q: What happens if I stop taking Jiaxin suddenly?

A: When using any antibiotic, patients are generally advised to complete the full prescribed course of treatment. Official safety guidance states that abrupt discontinuation of the medicine must only occur after consulting with a healthcare professional.

Q: Do I need to have regular blood tests while I am taking Jiaxin?

A: Official safety guidelines recommend monitoring specific clinical parameters during the course of treatment. This may include regular checks of kidney function tests and, for those with diabetes, careful monitoring of blood glucose levels.

Q: Are there any known interactions between Jiaxin and alcohol?

A: A specific interaction study with alcohol may not be detailed in the official label. However, as a general precaution, combining any antibiotic with alcohol may increase the occurrence or severity of common side effects such as dizziness or stomach upset.

Q: How does Jiaxin affect blood pressure or heart rate?

A: The official safety profile for the medicine includes warnings regarding the potential for QT prolongation. This is a type of abnormal heart rhythm that could lead to more serious cardiac issues, and it is a key consideration in the official product information.

Q: What is the usual amount of time it takes to see the full expected effect of Jiaxin?

A: Official regulatory documents generally do not specify the exact amount of time it takes for a person to reach the full clinical effect of the medicine. The duration of the treatment course varies depending on the infection being treated.

Q: Can Jiaxin be taken with caffeine?

A: Official drug interaction information may not specifically detail an interaction with caffeine. However, the medicine is in a class known to interact with compounds such as theophylline, which is chemically related to caffeine, potentially increasing the body’s exposure to the medicine.

Q: Is Jiaxin a controlled substance?

A: According to official regulatory information, the medicine has not been reported to have any habit-forming tendencies. Therefore, its regulatory classification does not identify it as a controlled substance with respect to dependence potential.

Q: Does Jiaxin interact with birth control pills?

A: Official regulatory documents do not typically list this medicine as one that reduces the effectiveness of hormonal birth control (such as contraceptive pills, patches, or rings).

Q: Are headaches a common temporary side effect of starting Jiaxin?

A: According to the official safety profile, headaches are listed as one of the common side effects of the medicine. This is part of the established safety data for the drug.

Q: Does Jiaxin affect the ability to drive or operate machinery?

A: Due to the potential for side effects such as dizziness and drowsiness, the official product information includes a warning that the medicine may affect a person's ability to drive or safely operate machinery.

Q: Is it possible to become dependent on Jiaxin?

A: Official safety information states that the medicine does not have reported habit-forming tendencies. There are no indications in regulatory documents that it poses a risk of dependence.

Q: What should I do if I think I might be experiencing a serious side effect from Jiaxin?

A: The official safety information advises that if a serious adverse reaction is suspected, immediate medical evaluation is necessary.

Q: Is Jiaxin safe to use with herbal remedies?

A: Official regulatory documents generally caution that the use of any herbal or dietary supplements must be reviewed with the prescriber.

Q: Can Jiaxin cause issues with eyesight?

A: The official safety profile notes the potential for ocular (eye-related) side effects. This includes symptoms such as blurred vision or other visual disturbances that have been documented in relation to the medicine.

Storage Conditions

Jiaxin (Prulifloxacin film-coated tablets) must be stored under specific environmental controls to maintain its quality and efficacy. The tablets must be stored below 30°C and protected from both light and moisture. To achieve this protection, the medicine should always remain in its original blister package until immediately before use. Always check the packaging and do not use the medicine after its stated expiry date.

Disposal Instructions

Unused or expired Jiaxin must not be thrown away in household waste or flushed down the toilet (wastewater). Disposal must follow local regulatory requirements for medicinal products. Furthermore, the medicine must be stored out of the sight and reach of children to prevent accidental ingestion.